UNSPSC 51111824: Exemestane

This classification denotes a steroidal aromatase inhibitor with the molecular formula C20H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NY22HMQ4BX, chemically known as 6-methyleneandrosta-1,4-diene-3,17-dione but generally known as exemestane, which bears US NIH Compound Identifier 60198. European Medicines Agency schedules Exemestane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07492MIG.

UNSPSC 51111824 Exemestane, a Commodity code, covers the procurement of this specific aromatase inhibitor pharmaceutical used in breast cancer treatment. State and local governments acquire exemestane primarily through pharmacy benefit management programs, employee health plans, and Medicaid and state employee benefit programs. The work involves sourcing the drug through established pharmaceutical supply chains, often coordinated through group purchasing organizations, pharmacy benefit managers, or direct-to-manufacturer arrangements. Issuing bodies soliciting under this code include state health and human services agencies responsible for pharmacy benefits, state employee health plan administrators, and Medicaid programs serving eligible beneficiaries across multiple jurisdictions.

Texas Health and Human Services Commission posted Request for Information RFI HHS0017013 in April 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking detailed information from potential vendors about establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management. The RFI, with a response deadline of April 3, 2026, solicited vendor experience with direct contracting for self-insured employers and health plans in both private and government sectors within the prior two years, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. This preliminary market intelligence phase precedes formal competitive solicitation and reflects the state's exploration of alternative procurement pathways for pharmaceutical sourcing outside traditional pharmacy benefit manager and group purchasing organization channels.